Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
5
×
Tags
boston blog main
boston top stories
life sciences
national blog main
national top stories
5
×
patisiran
5
×
akcea therapeutics
alnylam pharmaceuticals
boston
clinical trials
fda
hereditary transthyretin amyloidosis
inotersen
new york blog main
new york top stories
san diego blog main
san diego top stories
tafamidis
drugs
onpattro
pfizer
rna interference
biotech
san francisco blog main
san francisco top stories
vyndaqel
alexion pharmaceuticals
andrew fire
anylam pharmaceuticals
barry greene
boehringer ingelheim
boston university
cardiomyopathy
craig mello
dan ollendorf
deals
dicerna pharamceuticals
european medicines agency
harvard pilgrim health care
hepatitis b
What
alnylam
drug
fda
medicine
ago
approved
disease
gene
medicines
patients
pharmaceuticals
protein
rna
rnai
uses
afternoon
akcea
alnylam’s
amyloidosis
approve
approves
attr
available
awaits
battle
biological
caught
causing
cells
crossed
debilitating
decades
decision
dicerna
discovered
ema
employ
europe
eye
fingers
Language
unset
Current search:
patisiran
×
photo
×
" national top stories "
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision